Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer

Nicola Principi, V. Preti, Stefania Gaspari, Antonella Colombini, Marco Zecca, Leonardo Terranova, Maria Giuseppina Cefalo, V. Ierardi, Claudio Pelucchi, Susanna Esposito

Research output: Contribution to journalArticle

Abstract

Patients with cancer, particularly those with hematologic malignancies, are at an increased risk of invasive pneumococcal disease (IPD) and they are included in the list of subjects for whom pneumococcal vaccination is recommended. The main aim of this study was to evaluate Streptococcus pneumoniae colonization in school-aged children and adolescents with cancer to determine the potential protective efficacy of 13-valent pneumococcal conjugate vaccine (PCV13). An oropharyngeal swab was obtained from 277 patients (age range 6-17 years) with cancer during routine clinical visits and analyzed for S. pneumoniae using real-time polymerase chain reaction. S. pneumoniae was identified in 52 patients (18.8%), including 47/235 (20.0%) with hematologic malignancies and 5/42 (11.9%) with solid tumors. Colonization declined significantly with an increase in age (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.16-0.71, and OR 0.30, 95% CI 0.11-0.82 in children aged 10-14 and ≥15 years, respectively, as compared to those

Original languageEnglish
Pages (from-to)301-307
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Streptococcus pneumoniae
Hematologic Neoplasms
Neoplasms
Odds Ratio
Confidence Intervals
Conjugate Vaccines
Real-Time Polymerase Chain Reaction
Vaccination

Keywords

  • cancer
  • children
  • pediatrics
  • pneumococcal conjugate vaccine
  • pneumococcal infection
  • pneumococcal vaccine
  • Streptococcus pneumoniae
  • tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer. / Principi, Nicola; Preti, V.; Gaspari, Stefania; Colombini, Antonella; Zecca, Marco; Terranova, Leonardo; Cefalo, Maria Giuseppina; Ierardi, V.; Pelucchi, Claudio; Esposito, Susanna.

In: Human Vaccines and Immunotherapeutics, Vol. 12, No. 2, 01.02.2016, p. 301-307.

Research output: Contribution to journalArticle

Principi, Nicola ; Preti, V. ; Gaspari, Stefania ; Colombini, Antonella ; Zecca, Marco ; Terranova, Leonardo ; Cefalo, Maria Giuseppina ; Ierardi, V. ; Pelucchi, Claudio ; Esposito, Susanna. / Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer. In: Human Vaccines and Immunotherapeutics. 2016 ; Vol. 12, No. 2. pp. 301-307.
@article{d82c99f4074a4b358040c6b5ee2d08c7,
title = "Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer",
abstract = "Patients with cancer, particularly those with hematologic malignancies, are at an increased risk of invasive pneumococcal disease (IPD) and they are included in the list of subjects for whom pneumococcal vaccination is recommended. The main aim of this study was to evaluate Streptococcus pneumoniae colonization in school-aged children and adolescents with cancer to determine the potential protective efficacy of 13-valent pneumococcal conjugate vaccine (PCV13). An oropharyngeal swab was obtained from 277 patients (age range 6-17 years) with cancer during routine clinical visits and analyzed for S. pneumoniae using real-time polymerase chain reaction. S. pneumoniae was identified in 52 patients (18.8{\%}), including 47/235 (20.0{\%}) with hematologic malignancies and 5/42 (11.9{\%}) with solid tumors. Colonization declined significantly with an increase in age (odds ratio [OR] 0.34, 95{\%} confidence interval [CI] 0.16-0.71, and OR 0.30, 95{\%} CI 0.11-0.82 in children aged 10-14 and ≥15 years, respectively, as compared to those",
keywords = "cancer, children, pediatrics, pneumococcal conjugate vaccine, pneumococcal infection, pneumococcal vaccine, Streptococcus pneumoniae, tumor",
author = "Nicola Principi and V. Preti and Stefania Gaspari and Antonella Colombini and Marco Zecca and Leonardo Terranova and Cefalo, {Maria Giuseppina} and V. Ierardi and Claudio Pelucchi and Susanna Esposito",
year = "2016",
month = "2",
day = "1",
doi = "10.1080/21645515.2015.1090071",
language = "English",
volume = "12",
pages = "301--307",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor and Francis Inc.",
number = "2",

}

TY - JOUR

T1 - Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer

AU - Principi, Nicola

AU - Preti, V.

AU - Gaspari, Stefania

AU - Colombini, Antonella

AU - Zecca, Marco

AU - Terranova, Leonardo

AU - Cefalo, Maria Giuseppina

AU - Ierardi, V.

AU - Pelucchi, Claudio

AU - Esposito, Susanna

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Patients with cancer, particularly those with hematologic malignancies, are at an increased risk of invasive pneumococcal disease (IPD) and they are included in the list of subjects for whom pneumococcal vaccination is recommended. The main aim of this study was to evaluate Streptococcus pneumoniae colonization in school-aged children and adolescents with cancer to determine the potential protective efficacy of 13-valent pneumococcal conjugate vaccine (PCV13). An oropharyngeal swab was obtained from 277 patients (age range 6-17 years) with cancer during routine clinical visits and analyzed for S. pneumoniae using real-time polymerase chain reaction. S. pneumoniae was identified in 52 patients (18.8%), including 47/235 (20.0%) with hematologic malignancies and 5/42 (11.9%) with solid tumors. Colonization declined significantly with an increase in age (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.16-0.71, and OR 0.30, 95% CI 0.11-0.82 in children aged 10-14 and ≥15 years, respectively, as compared to those

AB - Patients with cancer, particularly those with hematologic malignancies, are at an increased risk of invasive pneumococcal disease (IPD) and they are included in the list of subjects for whom pneumococcal vaccination is recommended. The main aim of this study was to evaluate Streptococcus pneumoniae colonization in school-aged children and adolescents with cancer to determine the potential protective efficacy of 13-valent pneumococcal conjugate vaccine (PCV13). An oropharyngeal swab was obtained from 277 patients (age range 6-17 years) with cancer during routine clinical visits and analyzed for S. pneumoniae using real-time polymerase chain reaction. S. pneumoniae was identified in 52 patients (18.8%), including 47/235 (20.0%) with hematologic malignancies and 5/42 (11.9%) with solid tumors. Colonization declined significantly with an increase in age (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.16-0.71, and OR 0.30, 95% CI 0.11-0.82 in children aged 10-14 and ≥15 years, respectively, as compared to those

KW - cancer

KW - children

KW - pediatrics

KW - pneumococcal conjugate vaccine

KW - pneumococcal infection

KW - pneumococcal vaccine

KW - Streptococcus pneumoniae

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=84960965703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960965703&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1090071

DO - 10.1080/21645515.2015.1090071

M3 - Article

VL - 12

SP - 301

EP - 307

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 2

ER -